Drug Trial Radar · NCT06394713
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 15, 2024
Primary completion
Jun 15, 2025
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.
Conditions
- Advanced Malignant Neoplasm
Interventions
QLF31907Drug
intravenous administration, once every 3 weeks
IrinotecanDrug
intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
DocetaxelDrug
intravenous administration, 75mg/m2, d1, every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- phase Ib: Dose-limiting toxicity(DLT)Time frame: 28 days
- phase2: objective response rate(ORR)Time frame: up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.